Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanadelumab in Japanese Subjects With Hereditary Angioedema
NCT04180163Phase 3Completed
- Sponsor
- Takeda
- Start
- Dec 2019
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of lanadelumab in hereditary angioedema (HAE), sponsored by Takeda. Started Dec 2019; status: completed.
02
Drugs
lanadelumab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT04180163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04180163.